1例拉考沙胺致儿童药物性肝损伤病例分析并文献复习  

A Case of Drug-Induced Liver Injury Induced by Lacosamide in Children and Literature Review

作　　者：牛瑞 王熊 李欣坪 徐晓微 王婧雯 葛洁 Niu Rui;Wang Xiong;Li Xinping;Xu Xiaowei;Wang Jingwen;Ge Jie(Northwest Women and Children’s Hospital,Xi’an 710000,China;Ankang Maternal and Child Health Hospital,Shaanxi Ankang 725000,China;Panzhihua Central Hospital,Sichuan Panzhihua 617000,China;Xunyang People’s Hospital,Shaanxi Xunyang 725700,China;The First Affiliated Hospital of Air Force Medical University,Xi’an 710032,China)

机构地区：[1]西北妇女儿童医院,西安710000 [2]安康市妇幼保健院,陕西安康725000 [3]攀枝花市中心医院,四川攀枝花617000 [4]旬阳市人民医院,陕西旬阳725700 [5]空军军医大学第一附属医院,西安710032

出　　处：《儿科药学杂志》2025年第3期34-38,共5页Journal of Pediatric Pharmacy

基　　金：国家自然科学基金资助项目,编号72074218。

摘　　要：目的:探讨拉考沙胺(LCM)导致药物性肝损伤(DILI)的相关性和特点,为LCM的安全使用提供参考。方法:分析某院1例9岁儿童因治疗癫痫使用注射用LCM后导致DILI的案例,并复习国内外相关文献。结果:检索到国内外LCM致DILI相关文献共5篇,而本文为首例儿童使用LCM导致DILI的报道,分析发现在使用LCM治疗期间有可能会出现不同程度的DILI,主要为肝细胞损伤型,在停药或对症治疗后肝功能均逐步恢复正常。结论:LCM致DILI鲜有报道,肝损伤的病理机制尚不清楚,临床应考虑LCM致DILI的可能性,服药期间关注肝功能变化情况。Objective:To probe into the correlation and characteristics of drug-induced liver injury(DILI)induced by lacosamide(LCM),so as to provide reference for the safe use of LCM.Methods:A case of a 9-year-old child in a certain hospital who developed DILI induced by LCM for epilepsy treatment was analyzed.Relevant literature at home and abroad were reviewed.Results:A total of 5 domestic and foreign literature related to DILI induced by LCM were retrieved.This article was the first report of children with DILI induced by LCM.The analysis showed that DILI of different degrees may occur during the treatment of LCM,mainly liver injury type,and liver function returned to the normal state after drug withdrawal or symptomatic treatment.Conclusion:There are few reports of DILI induced by LCM,and the pathological mechanism of liver injury is not yet clear.In clinical practice,the possibility of DILI induced by LCM should be recognized,and changes in liver function should be monitored during medication.

关 键 词：拉考沙胺 药物性肝损害 儿童 药品不良反应 

分 类 号：R969.3[医药卫生—药理学]